TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orexo AB ( (SE:ORX) ) just unveiled an update.
Orexo AB is relocating to new premises in Uppsala Science Park as part of a strategic initiative to enhance its research and development capabilities. This move aims to foster greater collaboration, innovation, and sustainability while offering state-of-the-art laboratories and flexible office spaces. The new location is expected to reduce costs through efficient space utilization and lower energy consumption, thereby strengthening Orexo’s ability to attract and retain talent, which is crucial for developing future innovative medicines.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo is a Swedish pharmaceutical company with three decades of experience in developing improved pharmaceuticals using proprietary formulation technologies. The company focuses on providing innovative treatment solutions for opioid use disorder in the US market and collaborates with leading partners to develop products for other therapeutic areas globally. Orexo is listed on Nasdaq Stockholm and the OTCQX market in the US.
Average Trading Volume: 34,323
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.04B
For detailed information about ORX stock, go to TipRanks’ Stock Analysis page.